AB BioTechnologies selects Vanrx Pharmasystems aseptic filling and lyophilizer loading workcells
BLOOMINGTON, IN, March 7, 2017 /PRNewswire/ - AB BioTechnologies (AB), a provider of contract development and manufacturing services for the pharmaceutical industry, has selected Vanrx Pharmasystems to provide aseptic filling and lyophilizer loading systems for its new facility.
AB is expanding its services to enable customers to develop new drug products from preclinical through clinical trials using a single provider. The company's expansion into automated aseptic filling and lyophilization complements its existing offering of formulation, analytical services, lyophilization cycle development and GLP/tox manufacturing.
AB BioTechnologies will be the first company in the United States to operate a complete Vanrx system. The full system consists of the SA25 Aseptic Filling Workcell, Accumulator and Lyophilizer Loader. Vanrx is the only manufacturer to offer a gloveless robotic isolator system for aseptic filling and lyophilization of sterile injectable pharmaceuticals. Vanrx systems can support clinical and commercial drug production.
"The flexibility and aseptic assurance of the Vanrx system will enable us to provide exceptional service to pharmaceutical companies. Clients will be able to bring drug products to market faster, with stable formulations and with process development already well underway for commercial production," said Jeff Schwegman, Chief Executive Officer (CEO) of AB BioTechnologies.
"For a customer with Jeff's high level of knowledge to choose Vanrx is a vote of confidence in our approach. We share their view that more companies should be able to bring drugs that benefit patients to market," said Chris Procyshyn, CEO of Vanrx.
AB BioTechnologies is constructing a 23,000 square foot manufacturing facility in Bloomington, Indiana. The Vanrx aseptic filling equipment will be installed within a prefabricated modular cleanroom from Biologics Modular, and attached to a lyophilizer from SP Scientific. The SA25 will be installed for liquid GMP manufacturing by the fourth quarter of 2017, with added lyophilization capabilities beginning in 2018.
Vanrx Aseptic Filling Workcells enable the production of liquid or freeze-dried drug products in a variety of vial, syringe and cartridge formats. It is a fully integrated, automated aseptic filling system that combines robotics, gloveless isolator and machine vision technologies.
About AB BioTechnologies
AB BioTechnologies, Inc. is a contract service provider located in Bloomington, Indiana, providing pharmaceutical development and manufacturing services. AB BioTechnologies offers lyophilization cycle and process development services for injectable drugs, diagnostics, and tissue products. In conjunction with these services, AB BioTechnologies offers analytical and formulation development for large and small molecule, emulsions, suspensions, and oral solutions. The company was founded in February 2008 by J. Jeff Schwegman, Ph.D., as a teaching and consulting firm. Since then, AB BioTechnologies has quickly grown, expanding services and laboratory space, to keep up with client demand. For more information, visit us at www.ab-biotech.com.
About Vanrx Pharmasystems
Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, visit www.vanrx.com.
SOURCE Vanrx Pharmasystems Inc.
Share this article